Human cytomegalovirus DNA in cerebrospinal fluid

Jun Kohyama, Michiko Kajiwara, Masayuki Shimohira, Yoshihide Iwakawa, Hiroji Okawa

Abstract

To determine the involvement of human cytomegalovirus (CMV) in conditions of neurological impairment, detection of CMV DNA was attempted in cerebrospinal fluid obtained from 45 neurologically affected children aged from 1 month to 17 years by means of the polymerase chain reaction. Four patients (congenital CMV encephalopathy with West's syndrome, acute encephalitis, chronic epileptic encephalopathy, and lissencephaly) had CMV DNA in their cerebrospinal fluid. CMV DNA was absent in the cerebrospinal fluid of 11 neurologically unaffected controls aged from 1 month to 11 years. Three patients with acute CMV hepatitis had no CMV DNA in their cerebrospinal fluid. Among the four patients who had CMV DNA in their cerebrospinal fluid, two did not excrete CMV DNA or CMV antigen in the urine. The possible pathogenic significance of CMV DNA in the cerebrospinal fluid is discussed. By applying the polymerase chain reaction to cerebrospinal fluid, the mode of brain invasion by CMV can be clarified further.

(Arch Dis Child 1994; 71: 414–418)

Though the involvement of human cytomegalovirus (CMV) in various conditions of neurological impairment is suggested, conventional clinical diagnostic methods, such as virus isolation and demonstration of an increase in a specific antibody in the serum or cerebrospinal fluid, have not always succeeded in clarifying the direct relationship between CMV and each condition. Recently, the polymerase chain reaction, applied to cerebrospinal fluid, has been established as a rapid and accurate means of exploring the role of human CMV in the central nervous system of not only HIV infected patients but also non-HIV infected patients. In this study, we applied the polymerase chain reaction to the cerebrospinal fluid of patients with various neurological impairments and neurologically unaffected controls, who seemed to be free from HIV infection.

Patients and methods

Cerebrospinal fluid samples were obtained from 45 patients with various neurological impairments; their details are shown in tables 1 and 2. Another 11 samples obtained from neurologically unaffected patients (C1 to C11) served as controls (table 3). Of these 11 control samples, six were obtained from patients with malignancies who had to be given intrathecal drugs to prevent invasion of the malignant cells into the central nervous system (C1–C6). Among the 45 neurologically impaired patients, one had been diagnosed as suffering from congenital CMV encephalopathy (P42), and another had CMV retinitis associated with Wiskott–Aldrich syndrome (P43). Of the other 43 patients, six were diagnosed as having West's syndrome (P1–P6). P42 also had West's syndrome. There were three patients with neuronal migration disorders: lissencephaly (P45 and P6), and hemimegalencephaly (P7). The diagnosis of acute CMV hepatitis (C11, P8, and P9) was based on liver dysfunction with increase of a specific IgM titre for CMV.

Informed consent was obtained from all the subjects or their parents.

POLYMERASE CHAIN REACTION PROCEDURES

Thirty urine samples were examined for CMV DNA by the procedure reported elsewhere. We also applied this method to investigation of...
Table 2  Details of patients with human CMV DNA in their cerebrospinal fluid

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Diagnosis</th>
<th>Cerebrospinal fluid</th>
<th>Urine</th>
</tr>
</thead>
<tbody>
<tr>
<td>P42</td>
<td>4-2</td>
<td>F</td>
<td>Congenital CMV encephalopathy, West’s syndrome</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>P43</td>
<td>4-6</td>
<td>M</td>
<td>Acute encephalitis, Wiskott-Aldrich syndrome</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>P44</td>
<td>9-0</td>
<td>M</td>
<td>Chronic epileptic encephalopathy</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>P45</td>
<td>17-4</td>
<td>M</td>
<td>Lissencephaly</td>
<td>+</td>
<td>ND</td>
</tr>
</tbody>
</table>

CMV DNA on polymerase chain reaction: + (positive), - (negative), ND = not done.

*CMV antigen was not detected in urine with the shell vial culture method at the time when CMV DNA was detected in cerebrospinal fluid on the polymerase chain reaction.

cerebrospinal fluid samples. Aliquots of 50 µl of cerebrospinal fluid, which had been taken carefully to avoid blood contamination and preserved at under −80°C until treatment, was used as a template for the polymerase chain reaction.

Before DNA extraction samples were thawed and then centrifuged slowly to remove cellular components and other sediments; the supernatant was then used. To extract DNA, the procedure involving either glass paper12 or polyethylene glycol13 was employed.

A pair of oligonucleotide primers kindly provided by Iatron Laboratories (Chiba, Japan) was used. These primers (MIE primers) were selected from the CMV major immediate early gene exon 4 sequence, and the expected length of the amplified DNA product was 426 base pairs.12

The reaction mixture for the polymerase chain reaction consisted of 10 mmol/l Tris-hydrochloric acid (pH 8-3), 50 mmol/l potassium chloride, 1·5 mmol/l magnesium chloride, 200 µmol/l of each dNTP, 0·025 U/µl of Taq polymerase (all the latter components were from a GeneAmp polymerase chain reaction reagent kit; Perkin Elmer Cetus), 1 µmol/l of each primer, and 10 µl of a sample. To avoid cross contamination, the reaction mixture (without the sample) was prepared as a ‘master mix’, and divided into individual tubes. Cellular DNA was extracted from human CMV laboratory strain Towne infected cells as described previously and used as a positive control.14 All experiments simultaneously included positive and negative (no DNA sample) controls. Amplification (30 cycles) was performed with a program Temp Control System PC-700 (Astec Co). Each cycle comprised denaturation for one minute at 94°C, annealing for two minutes at 60°C, and primer extension for three minutes at 72°C. This cycle was followed by seven minutes at 72°C.

The reproducibility of the results was confirmed in each sample.

Results

CMV DNA was detected in the cerebrospinal fluid of four patients (table 2 and fig 1). The details of these patients are given in the following section. CMV DNA was not detected in any of the control samples (table 3). Three patients with acute CMV hepatitis (C11, P8, and P9) lacked CMV DNA in the cerebrospinal fluid (tables 1 and 3). Urinary secretion of CMV DNA was detected in six of eight control samples, and in eight of 22 neurologically affected patients’ ones (tables 1 and 3).

CASE REPORTS

P42

She was the second child of healthy non-consanguineous parents born at term after a normal pregnancy without any perinatal complications. She had suffered from intractable seizures from 3 weeks of age. Her head circumference at 6 weeks of age was 38 cm. Because of the increase of a specific IgM to CMV in both the serum and cerebrospinal fluid, congenital CMV encephalopathy was diagnosed. Though serial brain images showed no obvious abnormality including calcification or hydrocephalus, her psychomotor development was delayed. She presented a series of flexor spasms at 1·1 years, and electroencephalography (EEG) showed modified hypsarrhythmia. CMV DNA was detected in her cerebrospinal fluid at age 4±2 years. Although intrathecal interferon succeeded in eliminating CMV DNA from her cerebrospinal fluid, her seizures have not been controlled yet, in spite of various anticonvulsants.

P43

He was the first child of healthy non-consanguineous parents born at term after a normal pregnancy without any perinatal complications. He was diagnosed as having Wiskott-Aldrich syndrome at 1±4 years. Bone marrow transplantation using a haploidentical donor with T cell elimination was performed at 3±7 years of age. To control chronic graft versus host disease, he underwent immunosuppressive treatment. CMV DNA was

Figure 1 Southern hybridisation of polymerase chain reaction products. In all lanes, except for controls (lanes 6 and 7), the volume of the original cerebrospinal fluid (before precipitation) was 50 µl. Lanes 1 to 5: polymerase chain reaction products resulting from amplification of cerebrospinal fluid specimens obtained from P42-P45 and C3, respectively; lane 6: negative control; lane 7: positive control (DNA extracted from a fibroblast infected with CMV was used as the template); bp: base pair.

Table 3  Details of neurologically unaffected patients (control group)

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Diagnosis</th>
<th>Cerebrospinal fluid</th>
<th>Urine</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1</td>
<td>0-1</td>
<td>M</td>
<td>Familial erythropagocytic lymphohistiocytosis</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>C2</td>
<td>0-3</td>
<td>M</td>
<td>Familial erythropagocytic lymphohistiocytosis</td>
<td>-</td>
<td>ND</td>
</tr>
<tr>
<td>C3</td>
<td>3-0</td>
<td>F</td>
<td>Acute leukaemia</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>C4</td>
<td>6-0</td>
<td>M</td>
<td>Malignant lymphoma</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>C5</td>
<td>7-0</td>
<td>F</td>
<td>Acute leukaemia</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>C6</td>
<td>11-0</td>
<td>F</td>
<td>Acute leukaemia</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>C7</td>
<td>0-1</td>
<td>M</td>
<td>Pulmonary proteinosis</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>C8</td>
<td>0-4</td>
<td>M</td>
<td>Liver dysfunction, clot lip</td>
<td>-</td>
<td>ND</td>
</tr>
<tr>
<td>C9</td>
<td>1-0</td>
<td>M</td>
<td>Wiskott-Aldrich syndrome</td>
<td>(ND)</td>
<td>ND</td>
</tr>
<tr>
<td>C10</td>
<td>3-0</td>
<td>M</td>
<td>A sibling of a patient with congenital CMV infection</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>C11</td>
<td>0-9</td>
<td>M</td>
<td>CMV hepatitis</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

CMV DNA on polymerase chain reaction: + (positive), - (negative), ND = not done.
detected in his urine on the polymerase chain reaction, though CMV antigen was negative in his urine, as judged by means of the shell vial culture method. At 4-1 years of age, he was diagnosed as having CMV retinitis according to the clinical criteria. At 4-6 years, he began to show convulsions and his consciousness gradually deteriorated. The EEG findings (fig 2) were compatible with encephalopathy. CMV DNA was detected in his cerebrospinal fluid on the polymerase chain reaction, but CMV antigen was not found in his urine with the shell vial culture method. Serum antibody to HIV was not detected. In spite of the anti-CMV treatment (CMV monoclonal antibody and ganciclovir), he died at 4-7 years of age. Postmortem examination revealed zonal necrosis of the ventricular wall, and glial nodules in the substantia nigra and nucleus ruber of the mesencephalon. Although cytomegalic inclusion bodies were not found in the brain tissue, they were found in the bilateral adrenal medulla, kidneys, and pancreas.

P44
The details on this boy have been presented elsewhere. Briefly, he had suffered from intractable convulsions from the neonatal period, and serial brain images suggested gradual destruction of unilateral neural elements. No antibody to CMV nor HIV was detected in either his serum or cerebrospinal fluid. Immunoglobulin concentrations were normal. At 9 years of age, CMV DNA was detected in his cerebrospinal fluid but not in his urine. Intrathecal interferon succeeded in controlling his seizures. CMV DNA was still detected two weeks after the first intrathecal interferon administration, but it had disappeared a further two weeks later.

P45
He was the second child of healthy non-con- sanguineous parents born at term after a normal pregnancy without any perinatal complications. His parents noticed a delay in his psychomotor development at 9 months of age, and he was diagnosed as having cerebral palsy. He suffered from intractable seizures between 6 and 14 years of age. His psychomotor development was markedly delayed. At 17 years old, CMV DNA was detected in his cerebrospinal fluid. An antibody to CMV could be detected in his serum (ELISA IgG; x4), but not in his cerebrospinal fluid at that time. Magnetic resonance imaging of his brain revealed that he had lissencephaly.

Discussion
Application of the polymerase chain reaction to mononuclear cells in blood donors demonstrated that this method was more sensitive for detecting human CMV infection than serology. The detection of CMV antigen and/or CMV DNA has been believed to be a true positive result despite a negative culture. The polymerase chain reaction was also shown to be a reliable means of diagnosing central nervous system infections due to herpesvirus including CMV. The specificity of the polymerase chain reaction, applied to cerebrospinal fluid, in detecting CMV central nervous system involvement was established in patients infected by HIV. Also in immunocompetent hosts, CMV encephalitis was diagnosed on the basis of CMV DNA in cerebrospinal fluid detected on the polymerase chain reaction.

In the present study, human CMV DNA was not detected in the cerebrospinal fluid of the controls. Three patients with acute CMV hepatitis also had no CMV DNA in their cerebrospinal fluid. Invasion of CMV into the central nervous system must not always occur, even during the acute phase of CMV infection. Recently, the polymerase chain reaction revealed the persistence of genomic materials of herpes simplex virus within the human central nervous system even 17 years after acute encephalitis. The existence of CMV DNA in the cerebrospinal fluid of P42 indicated that the genomic material of CMV could persist in the central nervous system for at least four years. Detection of CMV DNA in the cerebrospinal fluid of P44 and P45 long after the probable CMV central nervous system invasion was possible.

Among the four patients presented, other than P42, none could be supposed to have CMV infection in the central nervous system according to the results obtained with conventional methods. Interestingly, P42 lacked typical features of congenital CMV infection. The time of central nervous system invasion and/or each host-agent interaction may modify the clinical picture. Moreover, she had West's syndrome. CMV has been known to be an agent inducing West's syndrome, and CMV DNA was detected in the CSF of a patient with West's syndrome on the polymerase chain reaction. Although there is an association between West's syndrome and CMV infection, six of the patients with West's syndrome (P1-P6) in this study lacked CMV DNA in their cerebrospinal fluid.

CMV retinitis could be diagnosed from specific retinal findings in P43, however, it was not obvious whether or not CMV was the
agent causing his encephalitis. As the established procedures for diagnosing CMV infection were of little use in this patient, the polymerase chain reaction had quite a crucial role in his diagnosis. On postmortem examination we observed glial nodules in his mesencephalon. Discrete glial nodules with a predilection for grey matter structures are suggestive of the presence of CMV encephalitis regardless of whether or not clinical encephalopathy is identified. Moreover, in CMV encephalitis, significantly more nodules have been reported to occur in the basal ganglia, diencephalon, and brain stem than in the cortical white matter. These facts strongly support the fact that P43 had suffered from CMV encephalitis.

In P44 we supposed that an isolated CMV invasion of the central nervous system or the time of CMV infection of the central nervous system might have made him immunotolerant to CMV, and thus caused his illness. Recently, a case of congenital and chronic CMV encephalitis found at necropsy was reported. Similar patients should be studied and attention should be paid to their brain pathology.

Regarding P45, there have been six reported patients with lisencephaly who have had congenital CMV infection diagnosed by established methods. In the present study, other patients with neuronal migration disorders (P6 and P7) had no CMV DNA in their cerebrospinal fluid. Sufficient to say that P45 supports the possibility that disturbance of neuronal migration can be brought about by CMV central nervous system invasion.

The ratio of positive CMV DNA in the urine of the controls (6/8) was higher than that in neurologically affected patients (8/22). However, the wide prevalence of asymptomatic CMV infection in Japan is known and CMV DNA in the urine is supposed to indicate the reactivation of CMV. The present results may reflect this wide prevalence, and may not mean a higher ratio of CMV infection in the controls than in the patients. Interestingly, we detected CMV DNA in the cerebrospinal fluid of patients who did not excrete CMV DNA (P44) or CMV antigen (P43) in their urine. The clinical significance of the detection of CMV DNA seems to be greater when CMV DNA is detected in the cerebrospinal fluid than in the urine.

We demonstrated that invasion of CMV into the central nervous system does not occur, even during the acute phase of CMV infection. Detection of CMV DNA in the cerebrospinal fluid hardly occurs in neurologically unaffected conditions. We have discussed the possible close association of CMV with each illness of patients who had CMV DNA in their cerebrospinal fluid. Though the time of central nervous system invasion remains to be determined in each of our patients, to prove the aetiologic role of CMV, the polymerase chain reaction must constitute a novel means of elucidating the pathogenesis in neurologically affected patients with an unknown origin based upon the results with conventional procedures.

By applying the polymerase chain reaction to the cerebrospinal fluid, the mode of invasion of CMV (or another virus) into the developing central nervous system can be clarified further. We conclude that the polymerase chain reaction is a new addition to the established techniques for diagnosing viral infections. We wish to thank Professor Junichi Yata for critically reading this manuscript.
Kohyama, Kajiwara, Shimohira, Iwakawa, Okawa

Human cytomegalovirus DNA in cerebrospinal fluid.

J Kohyama, M Kajiwara, M Shimohira, Y Iwakawa and H Okawa

Arch Dis Child 1994 71: 414-418
doi: 10.1136/adc.71.5.414

Updated information and services can be found at:
http://adc.bmj.com/content/71/5/414

These include:
Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/